Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography

Human Gene Therapy Methods

Volumn 23, Issue 1, 2012, Pages 56-64

  Lock, Martin ^a   Alvira, Mauricio R ^a   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; VIRUS VECTOR; RECOMBINANT DNA;

ADENO ASSOCIATED VIRUS; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BIOASSAY; CULTURE MEDIUM; EMBRYO; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS PARTICLE; GENE THERAPY; GENE VECTOR; GENETICS; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METHODOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; VIRION;

CHROMATOGRAPHY, ION EXCHANGE; DEPENDOVIRUS; DNA, RECOMBINANT; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC THERAPY; GENETIC VECTORS; MICROSCOPY, ELECTRON, TRANSMISSION; POLYMERASE CHAIN REACTION; VIRION;

EID: 84872030621     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2011.217     Document Type: Article

References (34)

1. Allay, J.A., Sleep, S., Long, S., et al. (2011). Good manufacturing practice production of self-complementary serotype 8 adenoassociated viral vector for a hemophilia B clinical trial. Hum. Gene Ther. 22, 595-604.
2. Ayuso, E., Mingozzi, F., Montane, J., et al. (2010). High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503-510.
3. Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239. (Pubitemid 351724452)
4. Brument, N., Morenweiser, R., Blouin, V., et al. (2002). A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes 2 and 5. Mol. Ther. 6, 678-686. (Pubitemid 35363701)
5. Chadeuf, G., Ciron, C., Moullier, P., and Salvetti, A. (2005). Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 12, 744-753. (Pubitemid 41350156)
6. Christine, C.W., Starr, P.A., Larson, P.S., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662-1669.
7. Clement, N., Knop, D.R., and Byrne, B.J. (2009). Large-scale adeno-associated viral vector production using a herpesvirusbased system enables manufacturing for clinical studies. Hum. Gene Ther. 20, 796-806.
8. Davidoff, A.M., Ng, C.Y., Sleep, S., et al. (2004). Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 121, 209-215. (Pubitemid 39295711)
9. Eberling, J.L., Jagust, W.J., Christine, C.W., et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70, 1980-1983.
10. Grimm, D., Kern, A., Pawlita, M., et al. (1999). Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322-1330. (Pubitemid 29359028)
11. Halbert, C.L., Metzger, M.J., Lam, S.L., and Miller, A.D. (2011). Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther. 18, 411-417.
12. Hauswirth, W.W., Aleman, T.S., Kaushal, S., et al. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990.
13. Kaludov, N., Handelman, B., and Chiorini, J.A. (2002). Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum. Gene Ther. 13, 1235-1243. (Pubitemid 34746703)
14. Kaplitt, M.G., Feigin, A., Tang, C., et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369, 2097-2105. (Pubitemid 46935946)
15. Lock, M., Alvira, M., Vandenberghe, L.H., et al. (2010a). Rapid, simple, and versatile manufacturing of recombinant adenoassociated viral vectors at scale. Hum. Gene Ther. 21, 1259-1271.
16. Lock, M., McGorray, S., Auricchio, A., et al. (2010b). Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum. Gene Ther. 21, 1273-1285.
17. Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. (Pubitemid 351724453)
18. Maguire, A.M., High, K.A., Auricchio, A., et al. (2009). Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374, 1597-1605.
19. Mingozzi, F., Maus, M.V., Hui, D.J., et al. (2007). CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422. (Pubitemid 46559826)
20. Moullier, P., and Snyder, R.O. (2008). International efforts for recombinant adeno-associated viral vector reference standards. Mol. Ther. 16, 1185-1188. (Pubitemid 351866048)
21. Okada, T., Nonaka-Sarukawa, M., Uchibori, R., et al. (2009). Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum. Gene Ther. 20, 1013-1021.
22. Qu, G., Bahr-Davidson, J., Prado, J., et al. (2007). Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J. Virol. Methods 140, 183-192. (Pubitemid 46185608)
23. Simonelli, F., Maguire, A.M., Testa, F., et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18, 643-650.
24. Smith, R.H., Levy, J.R., and Kotin, R.M. (2009). A simplified baculovirus-AAV expression vector system coupled with onestep affinity purification yields high-titer rAAV stocks from insect cells. Mol. Ther. 17, 1888-1896.
25. Sommer, J.M., Smith, P.H., Parthasarathy, S., et al. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol. Ther. 7, 122-128. (Pubitemid 36305364)
26. Thorne, B.A., Takeya, R.K., and Peluso, R.W. (2009). Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum. Gene Ther. 20, 707-714.
27. Timpe, J., Bevington, J., Casper, J., et al. (2005). Mechanisms of adeno-associated virus genome encapsidation. Curr. Gene Ther. 5, 273-284. (Pubitemid 40895012)
28. Urabe, M., Xin, K.Q., Obara, Y., et al. (2006). Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. Mol. Ther. 13, 823-828.
29. Virag, T., Cecchini, S., and Kotin, R.M. (2009). Producing recombinant adeno-associated virus in foster cells: Overcoming production limitations using a baculovirus-insect cell expression strategy. Hum. Gene Ther. 20, 807-817.
30. Wright, J.F. (2011a). Adeno-associated viral vector manufacturing: Keeping pace with accelerating clinical development. Hum. Gene Ther. 22, 913-914.
31. Wright, J.F. (2011b). New adeno-associated virus strategies to support momentum in the clinic. Hum. Gene Ther. 22, 519-521.
32. Xiao, W., Chirmule, N., Berta, S.C., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73, 3994-4003. (Pubitemid 29189844)
33. Zhang, H., Xie, J., Xie, Q., et al. (2009). Adenovirus-adenoassociated virus hybrid for large-scale recombinant adeno-associated virus production. Hum. Gene Ther. 20, 922-929.
34. Zhou, J., Yang, X., Wright, J.F., et al. (2011). PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9. J. Virol. Methods 173, 99-107.